105 results on '"Bolstad, Nils"'
Search Results
102. A Phase I Study of 177lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin’s B Cell Lymphoma
- Author
-
Kolstad, Arne, Madsbu, Ulf, Dahle, Jostein, Stokke, Caroline, Bach-Gansmo, Tore, Muftuler Løndalen, Ayca, Holtedahl, Jon Erik, Revheim, Mona Elisabeth, Bruland, Øyvind, Bolstad, Bjørg, Bolstad, Nils, Tierens, Anne, Larsen, Roy Hartvig, Alfheim, Jan Alan, Delabie, Jan, Signe, Spetalen, Erlanson, Martin, Nygaard Rudå, Stine, and Holte, Harald
- Abstract
Background and aim:The CD37 antigen is expressed at high levels predominantly by normal B cells and the majority of malignant B-cell lymphomas. Hence, this surface antigen represents an interesting therapeutic target for treatment of B-cell non-Hodgkin lymphomas (NHL). 177Lu-DOTA-HH1 (Betalutin™) is a novel anti-CD37 radioimmunoconjugate currently under clinical development. Betalutin™ consists of the β-emitting isotope Lutetium-177 (t/2 = 6.7 days) chelated to DOTA (a chemical linker) which is conjugated to the murine mAb HH1. Betalutin™ is delivered in a ready-to-use formulation at the study centers. Pre-clinical studies have demonstrated significant anti-tumor activity; both ex vivo and in models of human B-cell lymphomas in mice. Based on these results, a phase I study has been initiated in order to determine the maximum tolerated dose (MTD), overall safety and to explore tumor response.
- Published
- 2014
- Full Text
- View/download PDF
103. The Prevalence and Rate of Undiagnosed Celiac Disease in an Adult General Population, the Trøndelag Health Study, Norway.
- Author
-
Lukina P, Andersen IL, Klaasen RA, Warren DJ, Bolstad N, Mjønes P, Rønne E, Iversen R, Sollid LM, Lundin KEA, and Ness-Jensen E
- Abstract
Background & Aims: This study aimed to determine the total prevalence of celiac disease (CeD), including undiagnosed cases, in a population-based study of adults screened for CeD., Methods: The study used the fourth Trøndelag Health Study (HUNT4), conducted in 2017-2019, where 56,042 adult (aged >20 years) residents of Nord-Trøndelag County, Norway, participated. Serum samples from 54,505 participants were analyzed for anti-transglutaminase 2 IgA and IgG. Seropositive individuals were invited for a clinical assessment, including upper endoscopy with duodenal biopsies. Previously diagnosed and seronegative CeD cases were identified through linkage to hospital records and the Norwegian Patient Registry., Results: The rate of CeD seropositivity was 2.0% (1107/54,505). Out of these, 724 individuals attended the clinical assessment. Additionally, the hospital records and registry identified individuals with a known CeD diagnosis, that were seronegative or without serology in HUNT4 or seropositive in HUNT4 but did not participate in the clinical assessment. In total, the study confirmed a new CeD diagnosis after participation in HUNT4 in 470 individuals and a known CeD diagnosis before participation in HUNT4 in 383 individuals. The total biopsy-confirmed prevalence of CeD was 1.5% (853/56,042), and the ratio of new, previously undiagnosed CeD cases (after HUNT4) to known, previously diagnosed CeD cases (before HUNT4) was 1.2:1 (470/383)., Conclusions: The total prevalence of CeD in this population-based study of adults in Norway was high and many individuals were previously undiagnosed. Detection of CeD should be improved, because early diagnosis is crucial for effective management and prevention of complications., (Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
104. Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.
- Author
-
Brun MK, Gehin JE, Bjørlykke KH, Warren DJ, Klaasen RA, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Jahnsen J, Bolstad N, Jørgensen KK, Haavardsholm EA, Goll GL, and Syversen SW
- Subjects
- Adult, Male, Humans, Female, Middle Aged, Infliximab therapeutic use, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Drug Monitoring, Antibodies
- Abstract
Background: Antidrug antibodies to TNF inhibitors might affect clinical outcomes. Proactive therapeutic drug monitoring allows for early detection of antidrug antibodies and might reduce negative clinical consequences. We aimed to explore how antidrug antibodies to the TNF inhibitor infliximab influence treatment outcomes, and to assess the effect of proactive therapeutic drug monitoring., Methods: This was a predefined exploratory analysis of data from the randomised, controlled NOR-DRUM trials. The trials were conducted in rheumatology, gastroenterology, and dermatology departments at 21 Norwegian hospitals. Adult patients (aged 18-75 years) with immune-mediated inflammatory diseases were randomly assigned to proactive therapeutic drug monitoring or standard infliximab dosing in the NOR-DRUM A trial (30-week follow-up) and the NOR-DRUM B trial (52-week follow-up). Antidrug antibodies were assessed with a drug-sensitive assay before each infusion. The outcomes of remission (at week 30), disease worsening (during 52 weeks), infusion reactions, and infliximab discontinuation were assessed according to the presence of antidrug antibodies and use of therapeutic drug monitoring., Findings: Between March 1, 2017, and Dec 12, 2019, 616 patients were included in the NOR-DRUM trials, of whom 615 had at least one serum infliximab and antidrug antibody assessment and were included in the present analyses. Mean age was 45 years (IQR 32-56), 305 (50%) patients were women, and 310 (50%) patients were men. Antidrug antibodies were detected in 147 (24%) patients. Remission at week 30 occurred in 25 (35%) of 72 patients with antidrug antibodies and 180 (54%) of 335 without antidrug antibodies (risk ratio 0·62 [95% CI 0·45-0·86]; p=0·0037). In patients with antidrug antibodies compared with patients without antidrug antibodies, higher rates were found for: disease worsening over 52 weeks (0·76 per person-year vs 0· 35 per person-year, hazard ratio [HR] 2·02 [95% CI 1·33-3·07]; p=0·0009), infusion reactions (0·16 per person-year vs 0·03 per person-year, HR 17·02 [6·98-41·47]; p<0·0001), and infliximab discontinuation (1·00 per person-year vs 0·20 per person-year, HR 6·64 [4·84-9·11]; p<0·0001). These associations were more pronounced in patients with high concentrations of antidrug antibodies than in those with low concentrations of antidrug antibodies. Independent of antibody status, therapeutic drug monitoring was associated with a lower risk of disease worsening (HR 0·41 [0·29-0·59]; p=0·0001) or an infusion reaction (HR 0·30 [0·12-0·73]; p=0·0076), and was associated with an increase in the rate of infliximab discontinuation (HR 1·37 [1·02-1·83]; p=0·037)., Interpretation: In patients where antidrug antibodies were detected, remission was less likely to be reached and sustained, and infusion reaction or discontinuation of infliximab was more likely. Timely detection of antidrug antibodies by proactive therapeutic drug monitoring facilitated treatment decisions that reduced the negative consequences, both regarding infliximab effectiveness and safety. This highlights the role of proactive therapeutic drug monitoring in optimising infliximab therapy., Funding: Inter-regional KLINBEFORSK grants and South-Eastern Norway Regional Health Authority grants., Competing Interests: Declaration of interests KHB reports speakers' bureaus for Janssen-Cilag. ØS reports speakers' bureau from Boehringer Ingelheim. TKK reports grants from AbbVie, Bristol Myers Squibb, Amgen, Novartis, Pfizer, Galapagos, and UCB; consulting fees from AbbVie, Gilead, Janssen, Novartis, Pfizer, Sandoz, and UCB; speakers' bureau from Grünenthal, Janssen, and Sandoz; and advisory board participation for AbbVie. CM reports consulting fees from AbbVie, ACO, Almiral, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, LEO Pharma, Novartis, Perrigo, Pfizer, and Sanofi. JJ reported consulting fees from AbbVie, Pfizer, and Takeda; speakers' bureaus from AbbVie, Boerhinger Ingelheim, Bristol Myers Squibb, Celltrion, Galapagos, Hikma, Janssen Cilag, Novartis, Orion Pharma, Pfizer, Roche, Takeda, and Sandoz; and advisory board participation for AbbVie, Galapagos, Gilead, Janssen Cilag, Lilly, Pfizer, and Takeda. NB reports speakers' bureau from Roche, Janssen, and Novartis. KKJ reports speakers' bureau from Bristol Myers Squibb and Roche. EAH reports funding from The Norweigian Regional Health Authorities (inter-regional KLINBEFORSK grants) and The Norwegian Research Council (grant number 328657); speakers' bureaus from Pfizer and UCB; and advisory board participation for Pfizer and AbbVie. GLG reports consulting fees from AbbVie and Pfizer; and speakers' bureau from AbbVie, Pfizer, Sandoz, Celltrion, Lilly, UCB, and Boehringer Ingelheim. SWS reports funding from The South-Eastern Norway Regional Health Authority; and advisory board participation for AstraZeneca. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
105. Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.
- Author
-
Ueland T, Gullestad L, Kou L, Aukrust P, Anand IS, Broughton MN, McMurray JJ, van Veldhuisen DJ, Warren DJ, and Bolstad N
- Subjects
- Aged, Anemia blood, Anemia drug therapy, Biomarkers blood, Dose-Response Relationship, Drug, Female, Heart Failure drug therapy, Heart Failure physiopathology, Hematinics administration & dosage, Humans, Injections, Subcutaneous, Male, Middle Aged, Prognosis, Stroke Volume physiology, Anemia complications, Darbepoetin alfa administration & dosage, Gastrin-Releasing Peptide blood, Heart Failure complications
- Abstract
Aims: Neuroendocrine activation is associated with poor outcome in heart failure (HF). The neuropeptide gastrin-releasing peptide (GRP), derived from the precursor proGRP1-125 (proGRP), has recently been implicated in inflammation and wound repair. We investigated the predictive value of proGRP on clinical outcomes in HF patients with reduced ejection fraction., Methods and Results: The association between plasma proGRP (time-resolved immunofluorometric assay) and the primary endpoint of death from any cause or first hospitalization for worsening of HF was evaluated using multivariable Cox proportional hazard models in 1541 patients with systolic HF and mild to moderate anaemia, enrolled in the Reduction of Events by Darbepoetin alfa in Heart Failure (RED-HF) trial. Median proGRP levels in the RED-HF cohort were markedly increased [95 ng/L (25th, 75th percentile, 69-129 ng/L)] with 64% patients above the 80 ng/L reference limit. Baseline proGRP correlated with estimated glomerular filtration rate (r = 0.52), N terminal pro brain natriuretic peptide (r = 0.33), troponin T (r = 0.34), and haemoglobin (r = 0.16) (all P < 0.001). The incidence outcome increased with increasing tertiles of baseline proGRP (primary endpoint third tertile vs. the lowest tertile; hazard ratio 1.91; 95% confidence interval 1.60-2.28, P < 0.001). However, these associations were markedly attenuated and non-significant in adjusted models. No interaction between baseline proGRP and the effect of darbepoetin alfa treatment was detected. Moreover, no significant association between changes in proGRP during 6 month follow-up and outcome was observed., Conclusions: Pro-gastrin-releasing peptide is increased in patients with HF with reduced ejection fraction and anaemia, in particular in patients with poor renal function. However, proGRP adds little as a prognostic marker on top of conventional HF risk factors., (© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.